GlobeNewswire·Oct 7, 2025, 7:05 AM ET

Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases

Jade Biosciences unveiled JADE201, an investigational half-life extended & afucosylated monoclonal antibody targeting the B-cell activating factor receptor (BAFF-R) for autoimmune diseases.
JADE201 combines a dual mechanism of action with half-life extension technology to achieve deeper, more durable B cell depletion via enhanced antibody-dependent cellular toxicity & BAFF-R blockade.
Non-human primate studies demonstrated dose-dependent BAFF receptor occupancy, sustained B cell depletion after a single subcutaneous dose, & approximately a two-fold increase in half-life compared to ianalumab.
The first-in-human trial for rheumatoid arthritis is expected to begin in the first half of 2026 to assess safety, tolerability, pharmacokinetics, & pharmacodynamics.
The company will host a conference call & webcast on October 7, 2025, at 8:00 a.m. ET to discuss the JADE201 profile.
JADE201 builds on the clinical validation of BAFF-R targeting by addressing the short human half-life of current therapies like ianalumab to enable less frequent subcutaneous dosing.
The company's portfolio also includes JADE101, an anti-APRIL monoclonal antibody currently in Phase 1 trials for IgA nephropathy, & JADE-003, a preclinical discovery program.
Jade Biosciences positions JADE201 as a potential best-in-class therapy capable of treating a broad range of autoimmune diseases by overcoming limitations of existing B cell-directed treatments.